OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Cancer is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Revumenib: a new era in acute leukemia treatment	355
Subscription & copyright page	230
FBXW10: a male-biased E3 ligase in liver cancer	229
Spliced to kill: RNA mis-splicing derived cancer neoantigens	206
Platelets: tailoring metastasis treatment	189
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	181
Engineering growth factor ligands and receptors for therapeutic innovation	179
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	179
Tumor-resident microbes: the new kids on the microenvironment block	171
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	161
Navigating life as an early career researcher	159
Subscription and copyright page	157
Advisory Board and Contents	155
Subscription & copyright page	143
Onco-condensates: formation, multi-component organization, and biological functions	141
Accessing the vasculature in cancer: revising an old hallmark	140
Leveraging circulating microbial DNA for early cancer detection	132
Engine shutdown: migrastatic strategies and prevention of metastases	131
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	124
Radiotherapy and immunotherapy: open questions and future strategies	119
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	97
Subscription & copyright page	93
GOT2 consider the tumor microenvironment	92
Recent developments in myeloid immune modulation in cancer therapy	89
Neural hijacking in cancer metabolism: from nutrients to organelles	87

The evolving landscape of brain metastasis: volume II	87
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	83
Oncogenic competence: balancing mutations, cellular state, and microenvironment	83
Chromatin as an old and new anticancer target	82
Benefits and opportunities of the transgenic Oncopig cancer model	81
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	79
Cell death, therapeutics, and the immune response in cancer	79
Diet, nutrient supply, and tumor immune responses	75
Crosstalk of T cells within the ovarian cancer microenvironment	71
Tumor immunology CRISPR screening: present, past, and future	70
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	70
Chromosomal instability and aneuploidy as causes of cancer drug resistance	69
Regulation of metastatic organotropism	67
Gut microbiota – a double-edged sword in cancer immunotherapy	66
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	63
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	61
Advisory Board and Contents	60
Subscription & copyright page	59
Cancer catecholamine conundrum	58
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	58
Advisory Board and Contents	57
Scaling data toward pan-cancer foundation models	57
Advisory Board and Contents	55
Subscription & copyright page	55
Organellar pH as an emerging vulnerability to exploit in cancer	54
Palmitate paves the way to lung metastasis	54
Inflammation: the incubator of the tumor microenvironment	53
Insights on ErbB glycosylation – contributions to precision oncology	53